Pharmaceutical

AbbVie’s upadacitinib gains EU marketing authorisation for GCA

The EC has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with GCA.

Apr 10, 2025 - 06:00
AbbVie’s upadacitinib gains EU marketing authorisation for GCA
The EC has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with GCA.
Read the original article

Tags:

Previous Article

Obesity-related liver conditions: Understanding treatment options

Next Article

Revolutionary Scalable Graphene Membranes: A Breakthrough in Carbon Capture Tech...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Insights from ISPOR Europe 2023: Copenhagen

Insights from ISPOR Europe 2023: Copenhagen

Dec 14, 2023

Opinion: Public pharma is the best solution to the ongoing problem of drug shortages

Opinion: Public pharma is the best solution to the ongo...

Aug 9, 2023

Ethris and Lonza to develop mRNA vaccines for respiratory conditions

Ethris and Lonza to develop mRNA vaccines for respirato...

Apr 8, 2025